ALK and non-small cell lung carcinoma: Crizotinib is an inhibitor of ALK kinase activity that has been previously reported to achieve higher response rates and a significantly longer median progression‐free survival (PFS) than cytotoxic chemotherapy and was first approved in the various international markets for the standard treatment of patients with metastatic ALK‐positive NSCLC.5, 6, 7